RxDoctor Payments Data

Tracey Henry

Internal Medicine · Atlanta, GANPI 1710279955

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $304,593 of the $304,704 with a category attached, or 100.0%. Pacira Pharmaceuticals Incorporated accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $208,210 and has fallen 100.0% since, to $41 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$304,704in general payments, 2019–2025

Across 10 payments — averaging $30,470 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$305K
  • Johnson & Johnson$45
  • Inspire Medical Systems, Inc.$41
  • Vertex$25

What the payments were for

  • Food & beverage$1110%
  • Ownership interest$304,593100%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304,704 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$4,928
Medicare patients
40
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol31$40,604
OzempicSemaglutide17$34,331
JardianceEmpagliflozin20$23,327
JanuviaSitagliptin Phosphate14$20,319
XareltoRivaroxaban12$9,644
TrulicityDulaglutide11$9,010
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic19$1,360
Albuterol Sulfate HfaAlbuterol Sulfate36$1,082
Atorvastatin Calcium119$989
Ventolin HfaAlbuterol Sulfate12$778
Amlodipine-ValsartanAmlodipine Besylate/Valsartan22$662
Diclofenac Sodium21$619
Amlodipine Besylate101$597
Metoprolol Succinate24$505
Rosuvastatin Calcium46$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$9,64412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →